Cahill Represents Initial Purchasers in $1.5 Billion Senior Notes Offering for Valeant Pharmaceuticals International
Date: 03/26/18
Cahill represented the initial purchasers in connection with a Rule 144A/Regulation S offering of $1,500,000,000 aggregate principal amount of 9.250% senior notes due 2026 by Valeant Pharmaceuticals International, a pharmaceutical manufacturing company. Proceeds from the offering were used to refinance existing indebtedness.